# Giant Uterine Tumor Compatible With Sarcoma

## TL;DR

A 78-year-old woman with a large uterine tumor underwent surgery but died due to rapid disease progression, highlighting the challenges in diagnosing and treating uterine sarcomas.

## Contribution

This case report adds to the limited understanding of uterine sarcomas by describing a rare clinical scenario with rapid progression.

## Key findings

- The patient had a 6.115 kg uterine tumor, indicating a giant tumor size.
- The patient's condition worsened rapidly despite surgery and adjuvant treatment.
- Uterine sarcomas remain difficult to manage due to reliance on retrospective studies for treatment guidance.

## Abstract

Uterine sarcomas are a heterogeneous group of very rare tumors of mesenchymal origin, accounting for approximately 4% of malignant tumors of the uterus. These represent a heterogeneous group of neoplasms that are classified by histology in order of frequency as leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma or mixed mullerian tumor. Even in its early stages, uterine sarcoma has a bad prognosis and is a very rare disease that is difficult to identify and typically detected by anatomopathological studies. They are a type of cancer derived from the mesenchyme or connective tissue of the uterus that have a wide variety of histological aspects and biological activity, which makes their classification difficult. A 78-year-old woman reported experiencing abdominal pain, adynamia, and asthenia along with an increase in abdominal volume about six months ago. A physical examination revealed this increase, and a surgical procedure involving radical hysterectomy with peritoneal implants and pelvic lymph node dissection was chosen. The patient was transferred to the intensive care unit due to hypovolemic shock secondary to abdominal decompression and intraoperative hemorrhage, with a surgical product of 6.115 kilos. The patient had an adequate clinical evolution and was discharged one week later from the hospital for adjuvant treatment with chemotherapy and radiotherapy. However, after three weeks of follow-up, she died due to disease progression. Treatment recommendations for patients with uterine sarcoma are based on the results of retrospective studies, which makes clinical management difficult.